# US 2025/0145566 A1 · Phenethylamine derivatives, compositions, and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145566 A1
- Document ID: US20250145566A1
- Status: Published application
- Kind: A1
- Application number: 18/730,423
- Filed: 2023-02-15
- Published: 2025-05-08
- Earliest claimed: 2022-02-15
- Assignees: Cybin IRL Limited
- Applicants: Cybin IRL Limited
- Inventors: Alex Nivorozhkin; Joshua A. Hartsel; Clinton E. Canal; Francesco G. Salituro; Tina A. Mueller; Brett J. Greene; Alex Belser; Kenneth L. Avery; Amy Claire Reichelt; Geoffrey B. Varty; Michael Palfreyman
- Web page: https://patentgrep.com/patent/US20250145566A1

## CPC

- C07C 391/02: having selenium atoms bound to carbon atoms of six-membered aromatic rings
- A61P 25/00: Drugs for disorders of the nervous system
- C07C 217/60: linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C07C 323/32: having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
- C07D 317/58: Radicals substituted by nitrogen atoms (nitro radicals C07D317/52)
- C07D 327/04: Five-membered rings
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07C 2601/02: with a three-membered ring
- C07C 2601/08: the ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin receptor or monoamine transporter, such as inflammation, central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

## Claims

### Claim 1

A compound having a structure of Formula (I):
or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof,
wherein:
X1 and X2 are independently hydrogen, deuterium, or a substituted or unsubstituted C1-C6 alkyl;
Y1 and Y2 are independently hydrogen, deuterium, or a substituted or unsubstituted C1-C6 alkyl;
R2 and R3 are independently hydrogen, deuterium, halogen, a substituted or unsubstituted C1-C6 alkyl, —ORa, or —SRa;
R4 and R5 are independently hydrogen, deuterium, halogen, a substituted or unsubstituted C1-C6 alkyl, —ORa, —SRa, or —SeRa; or R4 and R5 together with the atoms attached thereto are optionally joined to form a heterocycloalkyl or heteroaryl;
R6 is hydrogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
R7 is a substituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
or alternatively R6 and R7 together with the nitrogen atom attached thereto are optionally joined to form a substituted or unsubstituted heterocycloalkyl;
each Ra is independently hydrogen, deuterium, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted C3-C10 cycloalkyl; and
wherein at least one of conditions (i)-(iii) are met
(i) at least one of X1, X2, Y1, Y2, R2, R3, R4, R5, R6, R7 comprises deuterium,
(ii) R4 and R5 together with the atoms attached thereto are joined to form a heterocycloalkyl or heteroaryl comprising deuterium or fluorine, and/or a benzo[d][1,3]oxathiole group,
(iii) R4 is —ORa, —SRa, or —SeRa, with Ra in R4 being a C1-C6 alkyl substituted with one or more halogen;
and with the proviso that when X1, X2, Y1, and Y2 are each hydrogen or deuterium, both R2 and R5 are not —ORa.

### Claim 2 (depends on 1)

The compound of claim 1, wherein at least one of X1, X2, Y1, Y2, R2, R3, R4, R5, R6, R7 comprises deuterium.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R4 and R5 together with the atoms attached thereto are joined to form a heterocycloalkyl or heteroaryl comprising deuterium or fluorine, and/or a benzo[d][1,3]oxathiole group.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R4 is —ORa, —SRa, or —SeRa, with Ra being a C1-C6 alkyl substituted with one or more halogen.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The compound of claim 1, having a structure of Formula (II):
or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof,
wherein:
X1 and X2 are independently hydrogen, deuterium, or a substituted or unsubstituted C1-C6 alkyl;
Y1 and Y2 are independently hydrogen, deuterium, or a substituted or unsubstituted C1-C6 alkyl;
R2 and R3 are independently hydrogen, deuterium, halogen, a substituted or unsubstituted C1-C6 alkyl, —ORa, or —SRa;
R6 is hydrogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
R7 is a substituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
or alternatively R6 and R7 together with the nitrogen atom attached thereto are optionally joined to form a substituted or unsubstituted heterocycloalkyl;
each Ra is independently hydrogen, deuterium, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted C3-C10 cycloalkyl;
A is O or S;
Z1 and Z2 are independently hydrogen, deuterium, or fluorine; and
when A is O, at least one of X1, X2, Y1, Y2, R2, R3, R6, R7, Z1, Z2 comprises deuterium, and/or at least one of Z1 and Z2 is fluorine.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R2 is —ORa.

### Claim 9 (depends on 7)

The compound of claim 7, wherein X1 and X2 are hydrogen.

### Claim 10 (depends on 7)

The compound of claim 7, wherein X1 and X2 are deuterium.

### Claim 11 (depends on 7)

The compound of claim 7, wherein X1 is hydrogen or deuterium, and X2 is a substituted or unsubstituted C1-C6 alkyl.

### Claim 12 (depends on 7)

The compound of claim 7, wherein A is S.

### Claim 13 (depends on 7)

The compound of claim 7, wherein A is O.

### Claim 14 (depends on 7)

The compound of claim 7, wherein Z1 and Z2 are hydrogen.

### Claim 15 (depends on 7)

The compound of claim 7, wherein Z1 and Z2 are deuterium.

### Claim 16

(canceled)

### Claim 17

A compound having a structure of Formula (III):
or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof,
wherein:
X1 and X2 are independently hydrogen, deuterium, or a substituted or unsubstituted C1-C6 alkyl;
Y1 and Y2 are independently hydrogen, deuterium, or a substituted or unsubstituted C1-C6 alkyl;
R4 is —SeRa;
R6 and R7 are independently hydrogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; or alternatively R6 and R7 together with the nitrogen atom attached thereto are optionally joined to form a substituted or unsubstituted heterocycloalkyl;
each Ra is independently hydrogen, deuterium, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted C3-C10 cycloalkyl; and
wherein Ra in R4 is a C1-C6 alkyl substituted with one or more halogen.

### Claim at position 17

18-21. (canceled)

### Claim 22 (depends on 17)

The compound of claim 17, which is selected from the group consisting of
or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.

### Claim at position 19

23-86. (canceled)

### Claim 87

A compound having a structure of Formula (IV):
or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof,
wherein:
X1 is hydrogen or deuterium;
X2 is a substituted or unsubstituted C1-C6 alkyl;
Y1 and Y2 are independently hydrogen or deuterium;
R3 is hydrogen or deuterium;
R4 is hydrogen, deuterium, halogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C3-C10 cycloalkyl, —ORb, —SRb, or —SeRb;
R6 and R7 are independently hydrogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; or alternatively R6 and R7 together with the nitrogen atom attached thereto are optionally joined to form a substituted or unsubstituted heterocycloalkyl;
each Ra is independently a substituted or unsubstituted C1-C6 alkyl; and
Rb is hydrogen, deuterium, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted C3-C10 cycloalkyl;
with the proviso that at least one of X1, X2, Y1, Y2, R3, R4, R6, R7, and Ra comprises deuterium and/or R4 is —ORb, —SRb, or —SeRb, with Rb in R4 being a C1-C6 alkyl substituted with one or more halogen.

### Claim 88 (depends on 87)

The compound of claim 87, which is selected from the group consisting of
or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.

### Claim at position 22

89-93. (canceled)

### Claim 94

A compound having a structure of Formula (V)
or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof,
wherein:
X1 and X2 are independently hydrogen, deuterium, or a substituted or unsubstituted C1-C6 alkyl;
Y1 and Y2 are independently hydrogen, deuterium, or a substituted or unsubstituted C1-C6 alkyl;
R4 and R5 are independently hydrogen, deuterium, halogen, a substituted or unsubstituted C1-C6 alkyl, —ORa, —SRa, or —SeRa; or R4 and R5 together with the atoms attached thereto are optionally joined to form a heterocycloalkyl or heteroaryl;
R6 and R7 are independently hydrogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; or alternatively R6 and R7 together with the nitrogen atom attached thereto are optionally joined to form a substituted or unsubstituted heterocycloalkyl;
each Ra is independently hydrogen, deuterium, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted C3-C10 cycloalkyl; and
Rb is hydrogen, deuterium, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted C3-C10 cycloalkyl.

### Claim 95 (depends on 94)

The compound of claim 94, which is selected from the group consisting of
or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.

### Claim at position 25

96-100. (canceled)
